Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
The Journal of Nervous and Mental Disease – March 04, 2014
Source: OpenAlex
Summary
Lysergic acid diethylamide (LSD) significantly reduced anxiety in 12 patients facing life-threatening illnesses. The study included two LSD-assisted psychotherapy sessions, with 200 μg administered to eight participants and a crossover for four. At the two-month follow-up, trait anxiety decreased by an impressive 1.1 effect size, while state anxiety saw a 1.2 effect size reduction. Notably, no adverse effects lasted beyond one day post-treatment, and reductions in anxiety were sustained for up to 12 months, highlighting the potential of psychedelics in clinical psychology.
Abstract
A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases. Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received either 200 μg of LSD (n = 8) or 20 μg of LSD with an open-label crossover to 200 μg of LSD after the initial blinded treatment was unmasked (n = 4). At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2, with no acute or chronic adverse effects persisting beyond 1 day after treatment or treatment-related serious adverse events. STAI reductions were sustained for 12 months. These results indicate that when administered safely in a methodologically rigorous medically supervised psychotherapeutic setting, LSD can reduce anxiety, suggesting that larger controlled studies are warranted.